Elsevier Provides Access to Reaxys® for Five Czech Universities to Optimize their Research in Chemistry
5-year access agreement supported by the European Structural Funds’ Operational Framework Program for Research, Development and InnovationPrague, Czech Republic, June 3, 2013
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced it has provided access to Reaxys, an online workflow solution for research chemists, for five Czech universities: the University of Pardubice, the Masaryk University, the Palacky University in Olomouc, the Tomas Bata University in Zlín and the University of Veterinary and Pharmaceutical Sciences Brno. The 5-year access agreement is supported by the European Structural Funds (ESF) through their Operational Framework Program for Research, Development and Innovation.
“The Czech Republic does not have an optimal solution to support the need for sustainable access to high quality global scientific research information for all its universities,” said Prof. Ing. Miroslav Ludwig, CSc, Rector of the University of Pardubice. “Funding from European Structural Funds to help secure access to basic information infrastructure in chemistry, chemical engineering and other related fields connected with sustainable development, opens doors to change this situation”.
Ms. Prochaskova, project coordinator of the Chemical Electronic Information Resources for R&D project at the University Pardubice said, “Reaxys’ content includes some of the most important information resources for chemistry and related fields. We are very pleased that access to Reaxys forms an essential part of the project and has been secured for these five Czech universities for the next five years.”
Lucie Vavrikova, Elsevier’s Country Manager for Czech Republic added, “We are very happy to support these universities by providing them with access to Reaxys. It is also worth mentioning that financing from the European Structural Funds to expand access to electronic resources such as Reaxys could also support other Central and Eastern European countries in their desire to improve their research performance.”
Reaxys is a unique workflow solution for researchers across all chemistry related domains. It is a key pillar of Elsevier Life Science Solutions, a suite of interoperable, domain-specific workflow solutions.
# # #
Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit Reaxys.
Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+49 172 6273 978